View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Clinical Trials Analysis
May 20, 2021updated 04 Apr 2022 4:51am

Rheumatoid Arthritis accounts for 18.9% share of global Immunology clinical trial activity in 2020

Rheumatoid Arthritis accounted for an 18.9% share of the global clinical trials within the Immunology therapy area in 2020, registering a decrease of 4.4% when compared with the last ten-year average of 23.3% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials for Rheumatoid Arthritis

Industry sponsored trials held a 61.1% share of all the clinical trials for Rheumatoid Arthritis indication in 2020, registering an increase of 2.7% when compared with the ten-year average of 58.4%. Non-industry sponsored trials accounted for a 38.9% share in 2020, marking a decrease of 2.7% over the ten-year average of 41.6%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Rheumatoid Arthritis trials

Asia-Pacific was the top region for industry sponsored Rheumatoid Arthritis trials, accounting for a 62.1% share in 2020, when compared with the five-year average of 58.2% and ten-year average of 49.0%.

Europe was at the second position with a 28.4% share in 2020, over the five-year average of 36.4% and ten-year average of 44.9%, followed by North America with a 20.0% share in 2020, as against five-year and ten-year averages of 26.2% and 32.5% respectively.

South and Central America stood fourth with a 5.3% share in 2020, compared with the five-year average of 9.5% and ten-year average of 13.0%, followed by Middle East and Africa with a 3.2% share in 2020, over five-year and ten-year averages of 7.9% and 10.4% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Rheumatoid Arthritis trials, accounting for a 47.4% share in 2020, as against the five-year average of 26.1% and ten-year average of 15.3%.

The US held a 17.9% share in 2020, over the five-year average of 22.5% and ten-year average of 28.9%, followed by Germany with an 11.6% share in 2020, compared with the five-year and ten-year averages of 15.8% and 16.3% respectively.

Poland held an 8.4% share in 2020, as against the five-year average of 15.5% and ten-year average of 16.6%.

Bulgaria held a 7.4% share in 2020, over the five-year and ten-year averages of 10.0% and 9.8% respectively.

Top regions of non-industry sponsored Rheumatoid Arthritis trials

Asia-Pacific was the top region for non-industry sponsored Rheumatoid Arthritis trials, accounting for a 47.5% share in 2020 when compared with the five-year average of 55.7% and ten-year average of 52.2%.

Europe was at the second position with a 35.6% share in 2020, over the five-year and ten-year averages of 23.4% and 27.3% respectively, followed by Middle East and Africa with a 10.2% share in 2020, as against the five-year average of 11.5% and ten-year average of 9.8%.

North America stood at the fourth position with a 5.1% share in 2020, compared with the five-year average of 9.7% and ten-year average of 10.8%, followed by South and Central America with a 1.7% share in 2020, over the five-year and ten-year averages of 1.8% and 1.8% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Rheumatoid Arthritis trials, accounting for a 20.3% share in 2020, as against the five-year average of 17.1% and ten-year average of 12.7%.

The Netherlands held a 13.6% share in 2020, over the five-year average of 3.8% and ten-year average of 5.3%, followed by Japan with a 10.2% share, compared with the five-year and ten-year averages of 18.0% and 25.4% respectively.

India held an 8.5% share in 2020, as against the five-year average of 15.1% and ten-year average of 9.7%.

France held a 6.8% share in 2020, over the five-year average of 3.6% and ten-year average of 4.2%.

Phase I trials lead industry sponsored clinical trials for Rheumatoid Arthritis in 2020

Phase I trials held a 65.7% share of industry sponsored clinical trials for Rheumatoid Arthritis in 2020, over the five-year average of 50.5% and ten-year average of 43.4%.

Phase IV trials held a 12.1% share in 2020, as against the five-year average of 15.3% and ten-year average of 19.3%. Phase II trials held an 11.1% share in 2020, compared with the five-year and ten-year averages of 16.7% and 18.6% respectively.

Phase III trials held an 11.1% share in 2020, over the five-year average of 17.4% and ten-year average of 18.8%.

Phase IV trials lead non-industry sponsored clinical trials for Rheumatoid Arthritis in 2020

Phase IV trials held a 46.0% share of non-industry sponsored clinical trials for Rheumatoid Arthritis in 2020, over the five-year average of 34.1% and ten-year average of 37.5%.

Phase II trials held a 31.7% share in 2020, as against the five-year average of 46.5% and ten-year average of 46.0%. Phase III trials held an 11.1% share, compared with the five-year and ten-year averages of 12.9% and 11.9% respectively.

Phase I trials held a 11.1% share in 2020, over the five-year average of 6.4% and ten-year average of 4.7%.

Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena